Singleton Hospital, South West Wales Cancer Institute, Sketty Lane, Swansea SA28QA, Wales, UK.
Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945.
Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the treatment of postmenopausal women with estrogen-receptor-positive disease.
The scientific literature on exemestane, including published articles and abstracts, was searched from 1988 to the present, and the most significant results are included in the review.
The review outlines the pharmacological characteristics of exemestane and the evidence supporting its use in the treatment of postmenopausal women with early or advanced estrogen-receptor-positive breast cancer.
Exemestane is an effective and well-tolerated aromatase inhibitor with a defined role in early-stage breast cancer following 2 - 3 years of adjuvant treatment with tamoxifen. Exemestane also has a role in the sequence of hormonal agents employed to control advanced hormone-sensitive breast cancer, in which clinicians may exploit its partial lack of cross-resistance with nonsteroidal aromatase inhibitors.
在绝经后妇女中抑制芳香酶可降低雌激素水平，这在激素敏感型乳腺癌的治疗中有价值。依西美坦是第三代甾体不可逆的芳香酶抑制剂，用于治疗绝经后妇女的雌激素受体阳性疾病的早期和晚期乳腺癌。
对依西美坦的科学文献进行了检索，包括已发表的文章和摘要，检索范围为 1988 年至今，并纳入了最有意义的研究结果。
综述概述了依西美坦的药理学特性及其在治疗早期或晚期雌激素受体阳性乳腺癌绝经后妇女中的应用证据。
依西美坦是一种有效的、耐受性良好的芳香酶抑制剂，在接受他莫昔芬辅助治疗 2-3 年后，在早期乳腺癌中具有明确的作用。依西美坦在用于控制晚期激素敏感型乳腺癌的激素药物序贯治疗中也有作用，在这种情况下，临床医生可以利用其与非甾体类芳香酶抑制剂部分缺乏交叉耐药性。
